Cathy N Lam

Array ( [id] => 14621905 [patent_doc_number] => 20190224320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 16/372958 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14621551 [patent_doc_number] => 20190224143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR N-PROPARGYLAMINE DERIVATIVE [patent_app_type] => utility [patent_app_number] => 16/370274 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17362627 [patent_doc_number] => 11229635 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Method of treating fibrosis [patent_app_type] => utility [patent_app_number] => 16/292266 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 28 [patent_no_of_words] => 22337 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16292266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118716 [patent_doc_number] => 11129825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Polysubunit opioid prodrugs resistant to overdose and abuse [patent_app_type] => utility [patent_app_number] => 16/286096 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 42741 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16286096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407133 [patent_doc_number] => 11248002 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Sesquiterpene derivative and use of the same in preparation of medicament for treating hepatitis b diseases [patent_app_type] => utility [patent_app_number] => 16/976463 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 9411 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16976463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16351812 [patent_doc_number] => 10792304 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-10-06 [patent_title] => Hemorheologic approach for reduction/prevention of cancer metastasis formation [patent_app_type] => utility [patent_app_number] => 16/277383 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 28 [patent_no_of_words] => 4527 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435525 [patent_doc_number] => 20190175634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => Method and Compositions for Treating Viral Infections [patent_app_type] => utility [patent_app_number] => 16/276063 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16276063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15663847 [patent_doc_number] => 10596129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use [patent_app_type] => utility [patent_app_number] => 16/272165 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6778 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15663849 [patent_doc_number] => 10596130 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use [patent_app_type] => utility [patent_app_number] => 16/272192 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6832 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956033 [patent_doc_number] => 11059875 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Composition for preventing or treating cardiofaciocutaneous syndrome [patent_app_type] => utility [patent_app_number] => 16/269984 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8764 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16269984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556033 [patent_doc_number] => 11312709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Ghrelin O-acyltransferase inhibitors [patent_app_type] => utility [patent_app_number] => 16/967262 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 27303 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406709 [patent_doc_number] => 20190169198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/265679 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435363 [patent_doc_number] => 20190175553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/257018 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16257018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306479 [patent_doc_number] => 20190142943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 16/248449 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306477 [patent_doc_number] => 20190142942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 16/247406 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15663845 [patent_doc_number] => 10596128 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use [patent_app_type] => utility [patent_app_number] => 16/224485 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6067 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16224485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210497 [patent_doc_number] => 20190117633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => TREATMENT OF DEPRESSIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/223356 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15631817 [patent_doc_number] => 10588876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use [patent_app_type] => utility [patent_app_number] => 16/224408 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6005 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16224408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506144 [patent_doc_number] => 20200385400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => SUBSTITUTED TETRAHYDROPYRAN DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/772536 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688293 [patent_doc_number] => 20210070769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/772428 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772428 [rel_patent_id] =>[rel_patent_doc_number] =>)